A Multi-Center, phase 1/2 Trial of AlloNK® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Puntos clave

• AlloNK cell therapy shows promise for relapsed or refractory non-hodgkin lymphoma patients, enhancing treatment options.
• The trial reports improved outcomes with a combination of AlloNK therapy and rituximab for select patients.
• Phase 1/2 trial designed to evaluate the safety and efficacy of AlloNK ± rituximab across multiple centers.
• These findings indicate a potential breakthrough in therapies for challenging cases of non-hodgkin lymphoma.